Loading
Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.
Mitazalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Alligator Bioscience AB, in pancreatic ductal adenocarcinoma. An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell.
1.Mitazalimab's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mitazalimab" OR ABSTRACT:"Mitazalimab" OR TITLE:"ADC-1013, JNJ-64457107" OR ABSTRACT:"ADC-1013, JNJ-64457107") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mitazalimab, not a curated reading list.
Shares CD40 and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.